Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company, has announced the granting of an equity award as a material inducement to employment. The grant, approved by the Company's Compensation Committee, includes the right to purchase 23,000 shares of Delcath's common stock. The options were granted on July 31, 2024, with an exercise price of $8.62, matching the closing price of Delcath's common stock on that date.
The vesting schedule for the options is as follows: one-third will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal monthly installments over the following 24 months. The options have a ten-year term and are subject to the employee's continued employment with Delcath. This award was granted in accordance with Nasdaq Listing Rule 5635(c)(4) and the terms of the Company's 2023 Inducement Plan.
Delcath Systems, Inc. (Nasdaq: DCTH), azienda di oncologia interventistica, ha annunciato il conferimento di un premio azionario come inducimento materiale all'impiego. Il conferimento, approvato dal Comitato per la Compensazione della Società, include il diritto di acquistare 23.000 azioni del capitale sociale comune di Delcath. Le opzioni sono state concesse il 31 luglio 2024, con un prezzo di esercizio di 8,62 dollari, corrispondente al prezzo di chiusura delle azioni comuni di Delcath in quella data.
Il piano di maturazione delle opzioni è il seguente: un terzo maturerà al primo anniversario della data di concessione, mentre i due terzi rimanenti matureranno in rate mensili uguali nei successivi 24 mesi. Le opzioni hanno un termine di dieci anni e sono soggette alla continuazione dell'impiego del dipendente con Delcath. Questo premio è stato conferito in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) e i termini del Piano di Inducimento 2023 della Società.
Delcath Systems, Inc. (Nasdaq: DCTH), una empresa de oncología intervencionista, ha anunciado la concesión de un premio en acciones como un incentivo material al empleo. La concesión, aprobada por el Comité de Compensación de la Compañía, incluye el derecho a adquirir 23,000 acciones de las acciones ordinarias de Delcath. Las opciones se otorgaron el 31 de julio de 2024, con un precio de ejercicio de $8.62, igualando el precio de cierre de las acciones ordinarias de Delcath en esa fecha.
El calendario de adquisición de las opciones es el siguiente: un tercio se adquirirá en el primer aniversario de la fecha de concesión, y los dos tercios restantes se adquirirán en cuotas mensuales iguales durante los siguientes 24 meses. Las opciones tienen un plazo de diez años y están sujetas al empleo continuado del empleado en Delcath. Este premio se otorgó de conformidad con la Regla de Cotización Nasdaq 5635(c)(4) y los términos del Plan de Inducimiento 2023 de la Compañía.
델캐스 시스템즈(Debcath Systems, Inc. (Nasdaq: DCTH))은 중재종양학 회사로, 고용 유도 자료로서 주식 보상을 부여한다고 발표했습니다. 이 보상은 회사 보상 위원회에 의해 승인되었으며, 델캐스의 보통주 23,000주를 구매할 수 있는 권리를 포함합니다. 이 옵션은 2024년 7월 31일에 부여되었으며, 행사 가격은 $8.62로, 해당 날짜의 델캐스 보통주의 종가와 일치합니다.
옵션의 배당 일정은 다음과 같습니다: 1/3은 부여일의 첫 번째 기념일에 배당되며, 나머지 2/3는 이후 24개월 동안 매달 균등한 금액으로 배당됩니다. 이 옵션은 10년의 조건을 가지며 델캐스에서의 직원의 계속 근무에 따라 달라집니다. 이 보상은 나스닥 상장 규정 5635(c)(4) 및 회사의 2023 유도 계획의 조건에 따라 부여되었습니다.
Delcath Systems, Inc. (Nasdaq: DCTH), une entreprise spécialisée en oncologie interventionnelle, a annoncé l'octroi d'un prix en actions en tant qu'incitation matérielle à l'emploi. L'octroi, approuvé par le Comité de Rémunération de la Société, comprend le droit d'acheter 23 000 actions de l'action ordinaire de Delcath. Les options ont été accordées le 31 juillet 2024, avec un prix d'exercice de 8,62 $, correspondant au prix de clôture de l'action ordinaire de Delcath à cette date.
Le calendrier d'acquisition des options est le suivant : un tiers sera acquis lors du premier anniversaire de la date d'octroi, les deux tiers restants étant acquis en versements mensuels égaux sur les 24 mois suivants. Les options ont une durée de dix ans et sont soumises à la continuation de l'emploi du salarié chez Delcath. Ce prix a été accordé conformément à la Règle d'inscription Nasdaq 5635(c)(4) et aux termes du Plan d'incitation 2023 de la Société.
Delcath Systems, Inc. (Nasdaq: DCTH), ein Unternehmen für interventionelle Onkologie, hat die Gewährung eines Aktienelements als wesentliche Anreiz für die Anstellung bekannt gegeben. Die Gewährung, die vom Vergütungsausschuss des Unternehmens genehmigt wurde, umfasst das Recht, 23.000 Aktien des Stammkapitals von Delcath zu erwerben. Die Optionen wurden am 31. Juli 2024 gewährt, mit einem Ausübungspreis von 8,62 USD, der dem Schlusskurs der Stammaktien von Delcath an diesem Datum entspricht.
Der Vesting-Plan für die Optionen sieht vor, dass ein Drittel am ersten Jahrestag des Gewährungsdatums fällig wird, während die verbleibenden zwei Drittel in gleichmäßigen monatlichen Raten über die folgenden 24 Monate fällig werden. Die Optionen haben eine Laufzeit von zehn Jahren und unterliegen der Fortsetzung der Beschäftigung des Mitarbeiters bei Delcath. Diese Auszeichnung wurde gemäß der Nasdaq-Listing-Regel 5635(c)(4) und den Bedingungen des Induktionsplans 2023 des Unternehmens gewährt.
- Delcath is attracting new talent with equity incentives
- The company has a structured equity compensation plan in place
- None.
The grant totaled the right to purchase an aggregate of 23,000 shares of the Company’s common stock and is subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The options were granted on July 31, 2024, the date the Compensation Committee approved the stock option included within the equity inducement and are subject to an exercise price equal to
The above-described award was granted in accordance with Nasdaq Listing Rule 5635(c)(4), and was granted pursuant to the terms of the Plan.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO KIT™ (melphalan for Injection/Hepatic Delivery System), approved for use in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812502182/en/
Investor Relations:
ICR Westwicke
investorrelations@delcath.com
Source: Delcath Systems, Inc.
FAQ
How many shares were granted in Delcath's (DCTH) recent equity award?
What is the exercise price for the stock options granted by Delcath (DCTH) on July 31, 2024?
What is the vesting schedule for Delcath's (DCTH) recently granted stock options?
Under which Nasdaq rule did Delcath (DCTH) grant the equity award?
